Imreg 2
Latest Information Update: 23 Aug 2002
At a glance
- Originator Imreg
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 17 Aug 1998 Phase-II clinical trials for Immunological disorders in USA (Unknown route)